Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric DIPG
NCT: NCT05615623 · ACTIVE_NOT_RECRUITING
Реклама
NCT IDNCT05615623
СтатусACTIVE_NOT_RECRUITING
Дата начала2023-01-04
Краткое описание
The purpose of this study is to evaluate the safety and efficacy of targeted blood brain barrier disruption with Exablate Model 4000 Type 2.0/2.1 in combination with Doxorubicin therapy for the treatment of DIPG in pediatric patients
Официальный источник
Открыть на ClinicalTrials.gov →Данные получены через API ClinicalTrials.gov. Актуальный статус смотрите в официальной записи.